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Abstract
The mechanism by which U-opioid receptor (Uor) modulated apoptosis was investigated in CNE2 human epithelial tumor
cells. Induction of these cells to undergo apoptosis with staurosporine was associated with a massive increase in intracellular
cAMP level. The inhibition of the increase in cAMP partially inhibited apoptosis as evidenced by a reduction of PARP and
caspase-3 cleavage. Accordingly, a low but significant level of apoptosis is induced in these cells by the elevation of cAMP
through the addition of forskolin and isobutylmethylxanthine. The existence of a cAMP-dependent and a cAMP-
independent apoptotic pathway is therefore suggested. Receptor binding studies, RT-PCR experiments and Western blot
analysis demonstrated the presence of type 1 Uor in the CNE2 cells. Stimulation of Uor in these cells resulted in the
production of inositol (1,4,5)-trisphosphate, reduction of cAMP level and a marked enhancement of staurosporine-induced
apoptosis. The potentiation of apoptosis by Uor was prevented by inhibition of phospholipase C but was slightly enhanced by
the presence of the active cAMP analogues, 8-CPT-cAMP and dibutyryl-cAMP. These data demonstrate for the first time
that the phospholipase C pathway activated by type 1 Uor expressed by cancer cells is involved in the potentiation of
apoptosis. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Opioids are commonly used in the suppression of
pain especially that arising from cancers [1,2]. The
pharmacological e¡ects of opioid compounds are
mediated by cell surface receptors that could be clas-
si¢ed into di¡erent types by ligand binding studies
using various pharmacological agonists/antagonists.
Subsequent cloning studies had identi¢ed genes that
coded for three main types of opioid receptors: the
W-, the U- and the N-subtypes [3,4]. Recently, receptor
molecules having cDNA sequences with substantial
homology to these classical opioid receptors were
discovered and they might have similar roles in
anti-nociception [5]. All known opioid receptors be-
long to the superfamily of G-protein-coupled recep-
tors which are characterized by the possession of
seven transmembrane hydrophobic regions. Cyclic
AMP is the earliest second messenger molecule
known to respond to stimulation of opioid receptors,
usually by a reduction of its intracellular level [6,7].
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In recent years, all three types of opioid receptors
were also demonstrated to couple to the inositol lip-
id/phospholipase C intracellular signaling pathway,
with the production of inositol 1,4,5-trisphosphate
and the increase in intracellular calcium ion level
[8]. In almost all cases, the G-protein that speci¢cally
couples to the opioid receptor is sensitive to pertussis
toxin, suggesting that it belongs to the G0/Gq sub-
family [9,10].
The expression of opioid receptors is not limited to
neuronal cells, as signi¢cant expression was also
demonstrated in numerous cell types [11^14]. Various
biological e¡ects had been attributed to these recep-
tors upon stimulation, such as cardiac arrhythmia,
inhibition of cell growth and division, and the con-
traction of intestinal smooth muscle [15^18]. It thus
seems reasonable to suggest that apart from playing
an important role in pain suppression, opioid recep-
tors expressed by non-excitable cells of peripheral
tissues are involved in the regulation of a much wider
spectrum of physiological activities. Many cancer
cells also express opioid receptors but the biological
signi¢cance of these receptors in such abnormal cells
has not received much attention. It was demon-
strated recently that stimulation of the W-receptor
either activated cellular survival or potentiated Fas-
induced apoptosis [19,20]. In immortalized embry-
onic neurons, stimulation of the U-opioid receptor
(Uor) was known to potentiate apoptosis due to a
lowering of the cAMP level [21]. An enhancement
of apoptosis in cancer cells by opioids had been
known for some time but the underlying mechanism
has not been determined. If the modulation of cAMP
level is the only mechanism that explains the promo-
tion of apoptosis by stimulated Uor, then the ques-
tion is raised as to whether the same e¡ect would still
occur for cells that utilize cAMP as a positive medi-
ator for apoptosis. Under such a circumstance, a
reduction of cAMP level due to stimulation of Uor
is expected to protect cells against apoptosis. To test
this hypothesis, we identi¢ed a cellular system that
utilizes cAMP as a positive signal for apoptosis. The
functional expression of endogenous Uor was also
demonstrated in this cell line. Contrary to the pre-
diction of the above hypothesis, stimulation of the
Uor resulted in the potentiation of apoptosis and
caused the hydrolysis of inositol lipids and reduction
of the cAMP level. We demonstrated that the poten-
tiation of apoptosis can be prevented by inhibition of
phospholipase C activity alone but not by supple-
mentation with cAMP analogues. Thus in CNE2
cells, the potentiation of apoptosis by Uor can be
mediated by a phospholipase C pathway. Our data
suggest that stimulation of Uor is expected to result
in enhancement of apoptosis, irrespective of whether
cAMP is acting as a positive or a negative mediator
of apoptosis.
2. Materials and methods
2.1. Materials
[3H]Bremazocine was from DuPont-NEN (USA);
[3H]nor-BNI and [3H]inositol were from American
Radiochemicals (USA); nor-BNI, trans-(3)-3,4-di-
chloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]ben-
zeneacetamide ([3]-U50,488H) and [+]-U50,488H
were from Tocris Cookson (UK); ( þ )-bremazocine,
DADLE, DAMGO, U-73122, and U-73343 were
from RBI (USA); the cyclic AMP assaying kit and
the Ins-1,4,5-trisphosphate assaying kit were from
Amersham (UK); polyclonal rabbit anti-human
PARP was from Upstate Biotechnology (Lake Plac-
id, NY); monoclonal mouse anti-human caspase-3
was from Transduction Laboratories (Lexington,
KY); all other chemicals and reagents were from
Sigma (USA).
2.2. Cell culture
The CNE-2 cell line was originally established
from an undi¡erentiated human nasopharyngeal car-
cinoma [22] and was a gift of Prof. W.F. Fong, City
University of Hong Kong. Cells were cultured in
RPMI 1640 medium supplemented with 5% fetal
calf serum and 100 IU/ml penicillin-streptomycin,
at 37‡C in a humidi¢ed atmosphere of 5% CO2
and 95% air.
2.3. Preparation of cell membranes
Cell membranes were prepared at 4‡C essentially
as described [23]. Con£uent CNE-2 cells grown in
100 mm culture dishes were washed twice with phos-
phate-bu¡ered saline (PBS) having the following
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composition (in mM): NaCl, 138; KH2PO4, 1.5;
KCl, 3; and Na2HPO4, 8.1; pH 7.4. The washed cells
were lysed by ¢rst undergoing an osmotic shock in
10 mM Tris-HCl bu¡er (pH 7.4). The lysed cells were
scraped from the plate and pelleted by centrifuga-
tion. The pellet was resuspended and homogenized
in a glass homogenizer in 10 ml of cold lysis bu¡er
(in mM): Tris-HCl, 50; PMSF, 0.5; EDTA, 1;
MgCl2, 2; DTT, 1; and CHAPS, 0.5; pH 7.4. The
resulting homogenate was centrifuged at 1000Ug for
10 min, and the supernatant collected. The pellet was
subject to homogenization for a second time, centri-
fuged and the supernatant was again saved. All of
the supernatants from the homogenization step were
combined and centrifuged at 180 000Ug for 45 min.
The resulting pellet containing the plasma mem-
branes was stored frozen at 370‡C until binding ex-
periments were performed. Protein concentration
was assayed by the method of Bradford [24], using
bovine serum albumin as a standard.
2.4. Receptor binding assay
Receptor binding experiments were performed es-
sentially as described [23]. The CNE2 cell plasma
membranes (100 Wg) were incubated with either
[3H]nor-BNI (0.5^100 nM) or [3H]bremazocine (1^
100 nM) in a 50 mM Tris-HCl bu¡er containing
bestatin (0.5 WM) and captopril (200 nM) at pH
7.4. The binding reaction was allowed to proceed
for 1 h at 25‡C in a volume of 1 ml and was termi-
nated by cooling rapidly in ice. The membrane-
bound 3H-ligand was separated from the unbound
fraction by rapid vacuum ¢ltration through a What-
man GF/B ¢lter. The ¢lter was washed three times,
each with a 4 ml aliquot of ice-cold 50 mM Tris-HCl
bu¡er (pH 7.4). The membrane-bound 3H-radioac-
tivity that was retained in the ¢lter was counted by
liquid scintillation counting. Non-speci¢c binding to
the plasma membranes was determined in the pres-
ence of a 1000-fold excess of the unlabeled ligand in
the binding reaction. Each binding reaction was per-
formed in triplicate. The equilibrium dissociation
constant (Kd) and the maximum binding capacity
(Bmax) were calculated by Scatchard plot analysis.
Ligand competition assays were performed by ¢rst
mixing CNE2 cell plasma membranes (100 Wg) with
[3H]bremazocine (25 nM) in exactly the same way as
described above for the receptor binding experi-
ments. Various concentrations of unlabeled compet-
ing ligands (U50,488H or DAMGO or DADLE)
were added to the reaction mixture for 1 h at 25‡C.
This was followed by cooling at 0‡C and vacuum
¢ltration to separate the free from the membrane-
bound ligand. The dissociation constant for the com-
peting ligand (Ki) was calculated according to the
equation:
K i  IC50=1 L=Kd
where IC50, [L] and Kd are respectively the concen-
tration of the competing ligand to achieve 50% inhi-
bition of [3H]bremazocine binding, the total concen-
tration of [3H]bremazocine and the dissociation
constant for the binding of bremazocine to the cell
membranes. The binding data were analyzed by the
Advanced EBDA/Ligand computer software pro-
gram which has a non-linear regression assay func-
tion. All values presented are means þ S.E.M.
2.5. Assay of [3H]inositol lipid metabolism in
U-agonist stimulated CNE2 cells
To study the turnover of inositol lipids in U-ago-
nist stimulated CNE2 cells, cellular inositol lipids
were ¢rst labeled with [3H]inositol. Con£uent
CNE2 cells (grown in 60 mm dishes) were washed
twice with serum-free RPMI medium. The cells were
then incubated with 3 ml of serum-free RPMI with
[3H]inositol (5 WCi/ml), for 4 h. At the end of this
labeling period, the radioactive medium was removed
and the cells were washed twice with PBS at 37‡C.
This was followed by incubating the cells in PBS
containing 10 mM LiCl for 30 min. To stimulate
the Uor, either U50,488H or the less active (+)-
U50,488H was added to the cells at a ¢nal concen-
tration of 50 WM. Stimulation was continued for 15
min and the medium was removed and the cells ex-
tracted for [3H]inositol phosphates with 5% perchlor-
ic acid. After neutralization of perchloric acid with
5 M KOH, the [3H]inositol phosphates were separated
by anion exchange chromatography [25]. For the
analysis of phospholipids, the perchloric acid pellet
was washed once and then resuspended in deionized
water (1 ml). The total phospholipids were extracted
with acidi¢ed chloroform/methanol (1:2 v/v) [26].
The washed organic phase containing all the labeled
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phospholipids was dried in air and then counted by
liquid scintillation counting.
2.6. Measurement of Ins(1,4,5)P3 mass level in
CNE2 cells
Con£uent CNE2 cells grown in 100 mm dishes
were quiesced overnight in serum-free RPMI. At
the time of the experiment, the cells were incubated
with PBS and U50,488H was added at a ¢nal con-
centration of 50 WM. To see whether the e¡ect was
Uor mediated, the cells were preincubated with the
U-antagonist nor-BNI (5 WM) 15 min prior to stim-
ulation with U50,488H. In all cases, the cells were
stimulated for 30 s and cellular reactions were termi-
nated rapidly by adding perchloric acid to a ¢nal
concentration of 5%. The quenched cells were cooled
on ice and scraped from the dishes. The entire cell
lysate was transferred to a centrifuge tube in which
the cell debris was subsequently pelleted. The super-
natant was saved, neutralized with 5 M KOH to pH
7.0. The Ins(1,4,5)P3 content was determined by the
Ins(1,4,5)P3 kit according to the manufacturer’s in-
structions (Amersham).
2.7. Assay for intracellular cAMP level in CNE2 cells
To measure the cAMP level in cells, the incubation
medium was aspirated and ice-cold ethanolic HCl
(1 ml) was added to the cells for the extraction of
cAMP. The quenched cells were scraped from the
dish, transferred to a centrifuge tube and stood for
5 min. The sample was centrifuged and the entire
supernatant was collected, freeze-dried and stored
at 320‡C for quantitation of cAMP content accord-
ing to the manufacturer’s instructions (Amersham).
The pellets were neutralized in 0.1 M NaOH for
protein determination by the method of Bradford
[24], using bovine serum albumin as a standard.
2.8. Induction and measurement of apoptosis in
CNE2 cells
Induction of apoptosis in CNE2 cells using stau-
rosporine was performed by a previously character-
ized procedure, whereby staurosporine was added to
CNE2 cells which had been quiesced in serum-free
medium for 12 h [27]. U50,488H and/or other com-
pounds was added to the cells for 1 h before their
treatment with staurosporine to induce apoptosis.
After incubation for 12^24 h, the cells are stained
with acridine orange and the number of cells which
had apoptotic features was counted as described [27].
Unless otherwise stated, the extent of apoptosis was
expressed as a percentage of cells stained positive for
apoptosis out of at least 500 cells examined.
2.9. Western blot analysis
For the analysis of PARP and caspase-3, quiescent
CNE2 cells were incubated with either SQ22336 at
1 mM or DDA at 250 WM for 15 min prior to the
addition of staurosporine at 50 nM for 12 h to in-
duce apoptosis. At the end of the 12 h period, the
cells were collected and analyzed for the cleavage of
PARP and caspase-3 exactly as described [27]. For
the analysis of Uor protein, CNE2 cells were scraped
from the culture dish and resuspended in phosphate
bu¡ered saline. After determination of cellular pro-
teins, a ¢xed amount of cells were lysed in a boiling
SDS-reducing sample bu¡er. After SDS-PAGE and
transfer to nitrocellulose membrane, the Uor was de-
tected with a polyclonal anti-Uor antibody that was
raised against a peptide in the N-terminal region of
Uor (Oncogene Science).
2.10. Identi¢cation of Uor transcript by RT-PCR
Total RNA was extracted from CNE2 cells with
the use of Trizol reagent (Gibco) following the man-
ufacturer’s instruction. Complementary DNA was
synthesized from 5 Wg of the extracted RNA, using
the M-MLV reverse transcriptase (Gibco) and oli-
go(dT) as primer in a reaction volume of 20 Wl.
Four microliters of the cDNA was ampli¢ed with a
pair of human Uor gene speci¢c primers having the
following sequences: 5P-CCGATACACAAAGAT-
GAAGACC-3P for the forward primer and 5P-
GTGCCTCCAAGGACTATCGCTG-3P for the re-
verse primer. Such a pair of primers predict a 341
bp fragment of the Uor cDNA. Ampli¢cation was
carried out with the use of Taq polymerase (Gibco)
according to the following PCR protocol: initial de-
naturation at 94‡C for 3 min, followed by a 35 cycle
program with 1 min at 94‡C, 1 min at 60‡C for
annealing, 1 min 50 s at 70‡C for extension, and a
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¢nal extension for 10 min at 70‡C. The PCR ampli-
¢cation product was analyzed by agarose gel electro-
phoresis.
2.11. Cloning and sequencing of PCR ampli¢cation
product
The PCR ampli¢cation products in the 300^400 bp
region in the agarose gel were excised and the DNA
fragments extracted using the Qiaquick kit (Qiagen).
The extracted DNA fragment was cloned into the
pCR2.1 plasmid by the TA cloning procedure (Invi-
trogen). White colonies were selected and screened
for the presence of DNA insert using Uor gene spe-
ci¢c primers. Positive white clones were regrown in
3 ml suspension cultures. The plasmid was harvested
and puri¢ed using the miniprep kit (Qiagen). The
DNA insert in the puri¢ed plasmid was sequenced
by the dye terminator method in both the forward
and reverse directions using the M13 primers. The
sequence information was analyzed by the GCG
software program.
2.12. Data analysis
Where necessary, statistical comparison was per-
formed with either the Variance or Student’s t-test.
3. Results
3.1. Accumulation of cAMP in CNE2 cells during
apoptosis
We previously obtained evidence that the addition
of the protein kinase inhibitor, staurosporine, to
CNE2 cells resulted in apoptosis [27]. To see whether
cAMP was involved in mediating the e¡ect of stau-
rosporine, the change in the level of this intracellular
second messenger in the CNE2 cells was determined.
Staurosporine was added to the cells over a range of
0^50 nM and the level of cAMP was measured after
an incubation period of 2 h. As shown in Fig. 1A,
staurosporine produced a massive increase in cAMP
in a dose-dependent manner. The level of cAMP
varies with the duration of treatment, as shown by
the results of time course experiments (Fig. 1B).
Maximum increase in cAMP was seen at approx.
2 h after the addition of staurosporine (50 nM) and
it declined to a level that was moderately above the
pretreatment level over the next 4 h. To investigate
whether this would implicate cAMP as a pro-apopto-
tic signal in the CNE2 cells, experiments were per-
formed to prevent the increase in cAMP induced by
staurosporine and the resulting e¡ect on apoptosis
was then measured. The cells were thus treated ¢rst
with either of the two inhibitors of adenyl cyclase,
SQ22536 and DDA. During such a pretreatment
step, the synthesis of cAMP would be blocked while
Fig. 1. Staurosporine induced a massive increase in cAMP level
in CNE2 cells. CNE2 cells were treated with di¡erent concen-
trations of staurosporine for 2 h and the cells were then
quenched and extracted for cAMP as explained. A marked in-
crease in the cAMP level could be seen at a staurosporine con-
centration of 20 nM or above. **Signi¢cantly di¡erent from the
control (i.e. not treated with staurosporine) with P6 0.01 (A).
The accumulation of cAMP was gradual and reached a maxi-
mum after approx. 2 h of treatment with staurosporine at a
concentration of 50 nM (B).
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existing cAMP molecules were catabolized by endog-
enous phosphodiesterase activity. Upon subsequent
treatment with staurosporine, the cAMP level would
not be able to increase since the synthesis of this
molecule had already been impaired by the presence
of the adenyl cyclase inhibitors. The cAMP level in
cells treated with such a procedure is shown in Fig.
2A. There was almost complete inhibition of increase
in the cAMP level. Moreover, such a drastic inhibi-
tion of cAMP production was associated with a sig-
ni¢cant though not complete decrease in staurospo-
rine-induced apoptosis (Fig. 2B). Consistent with this
observation, the addition of forskolin and isobutyl-
methylxanthine (IBMX) also resulted in a low level
of apoptosis. When forskolin or IBMX was added
alone, the extent of apoptosis was negligible. How-
ever, when both compounds are added together, the
Table 1
Induction of apoptosis in CNE2 cells by forskolin and IBMX
Reagents added Apoptosis (%)
Forskolin 0.6
IBMX 2.1
Forskolin and IBMX 11.4
CNE2 cells were incubated with either forskolin (20 WM) or
IBMX (2 mM) or both for 12 h. Apoptosis was measured by
acridine orange staining. The values are presented as
mean þ S.D. from data obtained from three similar experiments.
Fig. 2. Inhibition of staurosporine-induced increase of cAMP in CNE2 cells resulted in inhibition of apoptosis. (A) CNE2 cells were
treated with staurosporine alone or in the presence of either of the adenyl cyclase inhibitors SQ22536 or DDA for 1 h. The cells were
quenched and the cAMP extracted for determination as described. Staurosporine stimulated a massive increase in cAMP that could al-
most be totally suppressed in the presence of either SQ22536 or DDA. **Signi¢cantly di¡erent from the control with P6 0.01.
(B) CNE2 cells were treated with staurosporine alone or in the presence of either SQ22536 or DDA for 12 h and the percentage of
cells that had undergone apoptosis was determined. Both SQ22536 and DDA were able to substantially reduce the percentage of
apoptosis induced by staurosporine. Both SQ22536 and DDA on their own have little e¡ect on the cAMP level and the extent of
apoptosis in CNE2 cells. Data shown are representative of three independent experiments. Each determination is the mean þ S.D. of a
triplicate. *Signi¢cantly di¡erent from the value for staurosporine (STS) with P6 0.05. (C) Cells that had been treated as in panel B
were lysed with a bu¡er containing SDS. An aliquot of the lysate was analyzed by SDS-PAGE under reducing conditions. The pres-
ence of PARP and caspase-3 in the gel was then analyzed by Western blotting. Lanes: 1, staurosporine; 2, SQ2256 and staurosporine;
3, DDA and staurosporine; 4, SQ2256; 5, DDA.
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extent of apoptosis is 11%, which is slightly less than
half of the total apoptotic activity induced by stau-
rosporine (Table 1). To further examine how inhibi-
tion of the accumulation of cAMP would inhibit ap-
optosis, the proteolytic degradation of PARP and
caspase-3 was analyzed by Western blot analysis. In
cells pretreated with the adenyl cyclase inhibitors,
subsequent treatment with staurosporine resulted in
a decrease in the speci¢c proteolytic degradation of
the 116 kDa PARP and the 32 kDa caspase-3, in
contrast to the control sample in which the adenyl
cyclase inhibitors had been excluded (Fig. 2C).
3.2. Identi¢cation of Uor in CNE2 cells
The presence of opioid receptors in CNE2 epithe-
lial tumor cells was investigated using selective
opioid receptor ligands to compete with the binding
of the non-selective opioid receptor agonist
[3H]bremazocine to plasma membranes [28,29]. The
binding of [3H]bremazocine to the cell membranes
was saturable and the speci¢city for Uor was indi-
cated by the inability of DAMGO and DADLE,
which are speci¢c for the W- and Nor respectively,
to compete with [3H]bremazocine for the binding
sites. On the other hand, the Uor speci¢c U50,488H
was able to compete with the bound [3H]bremazocine
with an IC50 value of 204 þ 14.2 nM and a Ki value
of 150 þ 8.52 nM (Fig. 3). Furthermore, Scatchard
analysis of the binding of [3H]nor-BNI (a Uor antag-
onist) or [3H]bremazocine yielded a linear plot that
suggests the presence of one homogeneous popula-
tion of Uor species. The values of the dissociation
constant (Kd) and maximum binding capacity
(Bmax) for this Uor are listed in Table 2. The expres-
sion of Uor in the CNE2 cells was further tested for
by the presence of messenger RNA and receptor pro-
tein. Thus total RNA was extracted from the cells
and reverse transcription PCR was performed. Two
major PCR ampli¢cation products with the predicted
size in the 300^400 bp region could be detected (Fig.
4A). These two bands were separately excised, the
DNA fragments extracted, cloned and then se-
quenced. When the sequences obtained were used
to match with known cDNA sequences, the larger
of the two bands was found to have 98% homology
with the human type 1 Uor (Fig. 4B). The other band
was due to the glucose transporter gene that may
have arisen due to non-speci¢c ampli¢cation (data
not shown). To see whether the Uor transcript is ex-
pressed into the receptor protein, a total cell lysate
was prepared from CNE2 cells and analyzed by
Western blot analysis, using an antibody raised
Table 2
Dissociation constants (Kd) and maximum binding capacities
(Bmax) for the binding of U-opioid receptor speci¢c ligands, nor-
BNI and bremazocine, to the plasma membranes of CNE2 cells
Ligand Kd (nM) Bmax (fmol/mg protein)
[3H]Nor-BNI 26.79 þ 2.98 194.7 þ 13.36
[3H]Bremazocine 25.8 þ 2.1 206.6 þ 17.4
100 Wg of CNE2 cellular membranes were incubated with either
nor-BNI or bremazocine as described. The amount of either li-
gand that bound to the membranes speci¢cally was quanti¢ed.
The Kd and Bmax for the two ligands were derived by Scatchard
analysis. Both nor-BNI and bremazocine bind to the CNE2 cell
membranes with similar Kd and Bmax values.
Fig. 3. Selective displacement of bound [3H]bremazocine from
CNE2 cellular membranes by U50,488H. Plasma membranes
from CNE2 cells were prepared as described. Fixed amounts
(100 Wg) of the cellular membranes were incubated with the
general opioid receptor ligand [3H]bremazocine (25 nM) in the
presence of an opioid receptor subtype speci¢c agonist. The
amount of [3H]bremazocine that remained bound to the mem-
branes was measured and expressed as a percentage of the
control (i.e. speci¢c binding in the absence of any competing
ligand). R, DADLE; S, DAMGO; F, U50,488H. Only
U50,488H was capable of displacing the bound [3H]brema-
zocine with an IC50 of 204 þ 14.2 nM and a Ki of 150 þ 8.52
nM.
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against a peptide fragment in the N-terminal region
of the Uor. An approx. 48 kDa band that was specif-
ically recognized by the anti-Uor antibody was ob-
served, indicating the presence of the Uor protein
(Fig. 5).
3.3. Stimulation of U-opioid receptor potentiates
staurosporine-induced apoptosis
We next performed experiments to see whether
stimulation of the Uor would potentiate or inhibit
apoptosis. When staurosporine was added to cells
that had been pretreated with U50,488H at concen-
trations ranging from 0 to 100 WM, apoptosis was
signi¢cantly enhanced. Staurosporine alone caused
only approx. 24% of cells to undergo apoptosis.
However, in the presence of 50 WM U50,488H, a
statistically signi¢cant augmentation of apoptosis
was observed. The percentage of cells undergoing
apoptosis increased to about 50 in the presence of
100 WM U50,488H and represents an almost 100%
increase over the apoptosis obtained with staurospo-
rine alone (Fig. 6A). U50,488H on its own caused
insigni¢cant apoptosis throughout the concentrations
tested. To see whether the enhancement of apoptosis
by U50,488H was mediated by the Uor, the Uor spe-
ci¢c antagonist (nor-BNI) was also added together
Fig. 5. Western blot analysis for the type 1 Uor protein endoge-
nously expressed in the CNE2 cells. CNE2 cells were collected
by scraping and the cellular proteins were quanti¢ed. 15 Wg of
cellular proteins were analyzed by SDS-PAGE, followed by
transfer to nitrocellulose membrane. The Uor protein was visu-
alized by the ECL method using a polyclonal rabbit antibody
raised against a peptide fragment corresponding to the N-termi-
nal region of Uor, together with a HRP-conjugated anti-rabbit
second antibody. A major band was detected at a position that
has the size of Uor (approx. 48 kDa).
Fig. 4. Identi¢cation of type 1 Uor in CNE2 cells by reverse transcription PCR. Total RNA was extracted from cells as described in
Section 2. The mRNA in 5 Wg of total RNA was reverse transcribed using oligo(dT) as the primer. The cDNA synthesized was then
PCR-ampli¢ed using a pair of human type 1 Uor gene speci¢c primers. Two major PCR product DNA bands can be seen in lane 2
(A). Lanes: 1, DNA markers; 3, control PCR run in the absence of forward primer; 4, control PCR run in the absence of reverse
primer. These products were separately excised and extracted. The extracted DNA was cloned and sequenced. The larger DNA band
(approx. 350 bp) has 98% homology with the human type 1 Uor as calculated by the Basic Blast Search in the GCG program (B).
Unmatched bases are highlighted grey. PCR, the approx. 350 bp ampli¢cation product; hUor, human type 1 Uor (accession No.
U17298).
BBAMCR 14691 6-12-00
C.T.M. Diao et al. / Biochimica et Biophysica Acta 1499 (2000) 49^6256
with U50,488H to pretreat the cells. Under this con-
dition, the extent of apoptosis was very much the
same as that achieved with staurosporine alone.
This is not due to an inhibitory e¡ect of nor-BNI
on apoptosis since nor-BNI itself did not a¡ect stau-
rosporine-induced apoptosis. Addition of nor-BNI
alone also did not cause signi¢cant apoptosis. Thus
nor-BNI did not seem to act as an inhibitor or acti-
vator of cellular apoptosis (Fig. 6B). The loss of
enhancement e¡ect is therefore most likely due to
its property as a speci¢c Uor antagonist. Thus the
U50,488H-induced enhancement of apoptosis is
mediated by the Uor expressed in the CNE2 cells.
3.4. Intracellular signaling pathways mediating the
pro-apoptotic action of Uor
To study the molecular mechanism by which Uor
enhances apoptosis, the intracellular signals gener-
ated when it interacts with U50,488H were identi¢ed
by the following experiments. Cells were transiently
labeled with [3H]inositol for 4 h and then stimulated
with the speci¢c agonist U50,488H for 15 min. Ino-
sitol phosphates were extracted from the cells and the
increase in 3H-radioactivity associated with the ino-
sitol mono-, bis- and trisphosphates quanti¢ed. Pre-
liminary experiments showed that no statistically sig-
ni¢cant response in [3H]inositol lipid metabolism was
seen at concentrations of U50,488H below 10 WM.
At a higher concentration (50 WM) of U50,488H,
there was signi¢cant increase in the 3H-radioactivity
associated with the inositol monophosphate fraction
in the stimulated cells, in comparison to the unstim-
ulated control cells (Fig. 7A). A smaller, but also
signi¢cant increase was seen with the less potent ag-
onist (+)-U50,488H. There was also an approx. 100%
increase in phospholipid-associated 3H-radioactivity
extracted from the stimulated cells, with (+)-
U50,488H again giving rise to a smaller, approx.
60% increment (Fig. 7B). Direct mass measurement
was performed to see whether the increased turnover
of inositol lipids would produce Ins(1,4,5)P3. Stimu-
lation of cells with U50,488H for 30 s produced a
100% increase in the intracellular mass of In-
s(1,4,5)P3 and this response was abolished by the
simultaneous presence of the U speci¢c antagonist,
nor-BNI (Fig. 7C). These experiments suggested
that the Uor in the CNE2 cells were coupled to the
Fig. 6. U-Opioid receptor mediated potentiation of staurospo-
rine-induced apoptosis in CNE2 epithelial tumor cells. (A)
CNE2 cells were treated with various concentrations of
U50,488H or bu¡er (control) for 1 h before the addition of
staurosporine (R) at a ¢nal concentration of 20 nM to induce
apoptosis. 24 h later, the number of cells with morphological
evidence of apoptosis was quanti¢ed by the acridine orange as-
say. Signi¢cant potentiation of apoptosis could be seen at a
concentration of 10 WM of U50,488H. The magnitude of poten-
tiation increased markedly at 100 WM of U50,488H. The values
are presented as means þ S.D. from three independent experi-
ments. **;*P6 0.01 and 0.05, respectively, in comparison to the
control. (B) CNE2 cells were treated with either bu¡er,
U50,488H (100 WM) or U50,488H (100 WM) together with nor-
BNI (5 WM), for 1 h before staurosporine was added to induce
apoptosis. 24 h later, the number of cells with morphological
evidence of apoptosis was counted. Enhancement of apoptosis
was expressed as a percentage over that of the control cells
(treated only with staurosporine), taken to be 100%.
**;*P6 0.01 and 0.05, respectively, in comparison to the con-
trol. The presence of nor-BNI could completely suppress the
potentiating e¡ect of U50,488H.
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hydrolysis of inositol lipids with the production of
Ins(1,4,5)P3.
To see whether this signaling pathway was respon-
sible for the pro-apoptotic e¡ect of the Uor, the cells
were ¢rst treated with the speci¢c phospholipase C
inhibitor U73122 to inhibit the hydrolysis of inositol
lipids. Under this condition, there was no signi¢cant
Fig. 8. Inhibition of potentiation of apoptosis in U50,488H
treated CNE2 cells by the phospholipase C inhibitor U73122.
CNE2 cells were treated with U50,488H alone or in the pres-
ence of U73122 before addition of staurosporine (STS) to in-
duce apoptosis. After 24 h, the percentage of apoptotic cells
was measured. Potentiation of apoptosis was seen with pretreat-
ment of cells with U50,488H but this was abolished by co-incu-
bation with the PLC inhibitor U73122. The inactive analogue
of U73122, U73343, had no e¡ect on the potentiation of apo-
ptosis. **Signi¢cantly di¡erent from the control with P6 0.01.
Fig. 7. Stimulation of U-opioid receptor in CNE2 cells activated
the inositol lipid signaling pathway. [3H]Inositol-labeled CNE2
cells were stimulated with either U50,488H or its less active
form (+)-U50,488H for 15 min. The cells were quenched with
dilute perchloric acid (5% v/v). The [3H]inositol phosphates and
[3H]inositol lipids were extracted and analyzed as described.
Each determination was in triplicate expressed as mean þ S.D.
and the data are representative of three experiments.
**;*P6 0.01 and 0.05, respectively, in comparison to the con-
trol. Panel A shows that a signi¢cant increase in 3H-radioactiv-
ity could be seen in the inositol monophosphate fraction ob-
tained from cells stimulated with either agonist. Panel B shows
that the 3H-radioactivity was similarly increased in the total
phospholipids obtained from the stimulated cells. (C) CNE2
cells were stimulated with U50,488H alone or in the presence of
the speci¢c antagonist nor-BNI for 30 s and Ins(1,4,5)P3 was
extracted and assayed as described. An over 200% increase in
the Ins(1,4,5)P3 mass was observed in response to U50,488H
treatment. Data are mean þ S.D. of nine experiments.
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potentiation of apoptosis, suggesting that the activa-
tion of phospholipase C was responsible for the pro-
apoptotic e¡ect of Uor (Fig. 8).
We also investigated the possible involvement of
cAMP since this is a known intracellular messenger
regulated by opioid receptors. When the CNE2 cells
were stimulated by up to 10 WM of U50,488H for 15
min, no signi¢cant decrease in the intracellular
cAMP level was observed. However, at 20 WM or
above, there was a small but signi¢cant decrease in
the level of cAMP (Fig. 9). In the presence of stau-
rosporine, stimulation by U50,488H could still lead
to reduction of cAMP level. Thus in a typical experi-
ment, the level of cAMP after 6 h of staurosporine
treatment is 57 pmol/mg protein. With the simulta-
neous presence of U50,488H, the level was only 23.5
pmol/mg protein, indicating a reduction of about
50%.
Given the presence of a cAMP-dependent apopto-
tic pathway in the CNE2 cells (Figs. 1 and 2), the
lowering of the cAMP level is unlikely to account for
the potentiation of apoptosis. This idea was tested by
the supplementation of cell-permeable cAMP ana-
logues during treatment with U50,488H to see
whether it will eliminate the pro-apoptotic function
of Uor. CNE2 cells were therefore incubated with a
cAMP analogue (either 8-CPT-cAMP or dibutyryl-
cAMP) together with U50,488H, prior to the induc-
tion of apoptosis with staurosporine. However, the
presence of either cAMP analogue could not sup-
press the ability of U50,488H to potentiate apopto-
sis, in contrast to what was expected if the reduction
of intracellular cAMP level represented a signal for
the potentiation of apoptosis. Rather, the presence of
these cAMP analogues can even cause a slight in-
crease of staurosporine-induced apoptosis (Fig. 10).
4. Discussion
A number of previous studies suggested that
opioid receptors might play a role in enhancing ap-
optotic cell death but the underlying molecular
mechanism is not fully understood. Those intracellu-
lar signals modulated by the opioid receptors may,
however, be involved. Support for this hypothesis
came from the observation made by Goswami et
al. that in embryonic neurons, the Uor-induced low-
ering of the cAMP level and the enhancement of
apoptosis are causally related [21]. However, such a
mechanism may not be applicable to those cells in
which cAMP is a positive signal for apoptosis. This
Fig. 10. Cyclic AMP analogues have no e¡ect on the potentia-
tion of apoptosis by U50,488H. CNE2 cells were incubated
with U50,488H together with either dibutyryl-cAMP or 8-CPT-
cAMP for 1 h before staurosporine was added to induce apo-
ptosis. After 24 h, apoptosis was measured and expressed as a
percentage over that of the control in which the extent of apo-
ptosis was taken to be 100%.
Fig. 9. Downregulation of cAMP level in U-opioid receptor
stimulated CNE2 cells. CNE2 cells were treated with the adenyl
cyclase activator forskolin to elevate the intracellular cAMP lev-
el before stimulating the U-opioid receptor with U50,488H. The
cAMP was extracted from the cells and quanti¢ed. A signi¢cant
decrease in the cAMP level could be seen for U50,488H at or
above 20 WM. *;**Signi¢cantly di¡erent from the control (i.e.
not treated with U50,488H) with P6 0.05 and 0.01, respec-
tively.
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issue is being addressed in the present study by ex-
amining how Uor a¡ects apoptosis induced in the
epithelial tumor cell line CNE2.
We ¢rst investigated the role of cAMP in mediat-
ing apoptosis in these cells. The novel observation is
made that a massive increase in intracellular cAMP
level occurred upon treatment with staurosporine
(Fig. 1). It is at present not known exactly how stau-
rosporine stimulates an increase in cAMP. Neverthe-
less, since apoptosis was partially inhibited by the
prevention of cAMP increase, the role for cAMP
as a positive mediator for apoptosis in the CNE2
cells is strongly suggested. Our data suggest that
cAMP may act upstream from the activation of cas-
pase-3 since inhibition of staurosporine-induced ac-
cumulation of cAMP also resulted in partial inhibi-
tion of cleavage of caspase-3 and PARP (Fig. 2).
Furthermore, our data showed that addition of for-
skolin and isobutylxanthine together to elevate the
cAMP level could result in small but statistically sig-
ni¢cant apoptosis. These observations are in line
with several previous reports that cAMP was in-
volved in the regulation of apoptosis, by serving as
either a positive or a negative mediator. A number of
molecular targets were proposed for the apoptosis-
modulating e¡ects of cAMP, including the PKA, and
more recently BAD [30,31].
The Uor in CNE2 cells comprises a single homoge-
neous population of opioid agonist speci¢c binding
sites that is found to exist with signi¢cant abundance
(Fig. 3 and Table 2). Furthermore, they displayed the
same degree of a⁄nity and selectivity for speci¢c
U-opioid agonists as reported previously [32,33]. Using
a labeling approach with [3H]inositol, we obtained
direct evidence that stimulation of Uor led to turn-
over of inositol lipids. The extremely marked in-
crease of radioactivity in the inositol mono- and bis-
phosphate fraction is due to the increased production
and metabolism of inositol (1,4,5)-trisphosphate,
which is supported by the mass measurement of this
second messenger. However, the hydrolysis of phos-
phatidylinositol and phosphatidylinositol 4-phos-
phate may also contribute to the increase in inositol
mono- and bisphosphates. Since inositol trisphos-
phates are rapidly metabolized and only contribute
to a small percentage of total cellular inositol phos-
phates [34], a long incubation time (15 min) will miss
the peak of increase and the amount of this com-
pound harvested will not be enough for detection.
This may account for the apparent lack of a signi¢-
cant increase in the labeled inositol trisphosphate
fraction.
The RT-PCR and Western blot analyses demon-
strate that the Uor as detected by the binding studies
is type 1 Uor that has already been cloned and se-
quenced [35]. These results strongly support that the
U50,488H-induced signaling responses seen in the
present study are due to the activation of Uor and
not a result of non-speci¢c interaction. It is still un-
certain why U50,488H only at the micromolar level
can activate the inositol lipid and cAMP responses in
this cell type, an observation that is shared by the
Uor in rat cardiomyocytes [36^38]. The apparent dis-
crepancy between binding a⁄nity and dose-response
leads to the speculation that higher order molecular
interactions other than receptor-agonist binding may
be necessary, as exempli¢ed by the recently reported
dimerization of opioid receptors [39].
The stimulation of the Uor with a selective Uor
agonist U50,488H markedly potentiated staurospo-
rine-induced apoptosis (Figs. 6 and 7). This e¡ect
of U50,488H is exerted via the Uor since it could
be totally prevented by the speci¢c Uor antagonist
nor-BNI. The results demonstrate that in CNE2 cells
that express a cAMP-dependent apoptotic pathway,
the Uor could still exert an enhancing e¡ect on the
cell death process. The decrease in the level of cAMP
due to the activation of Uor was not responsible for
the apoptosis-enhancing e¡ect of the Uor because the
addition of active cAMP analogues did not prevent
the enhancement of apoptosis. On the other hand,
the inhibition of phospholipase C with U73122 was
shown to result in the loss of potentiation of apopto-
sis, suggesting the involvement of phospholipase C in
this process (Figs. 8 and 9). With the activation of
Uor, the cAMP level was reduced. In the CNE2 cells,
this resulted in a loss of activity of the cAMP-depen-
dent apoptotic pathway but the cells did not become
more resistant against apoptosis. In fact apoptosis
was enhanced by Uor activation through a phospho-
lipase C-dependent mechanism.
The phospholipase C catalyzed hydrolysis of ino-
sitol lipids will give rise to the production of In-
s(1,4,5)P3 and diacylglycerol, resulting respectively
in the mobilization of intracellular calcium ion and
the activation of protein kinase C. It is as yet uncer-
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tain which of these pathways is responsible for the
enhancing e¡ect of Uor on apoptosis. Several iso-
forms of protein kinase C were reported to partici-
pate in promoting cellular survival against apoptosis
[40,41]. We previously obtained evidence that in the
present cell system, protein kinase C was also in-
volved in an anti-apoptotic pathway activated upon
stimulation of the epidermal growth factor receptor
[27]. Since the presence of staurosporine should sup-
press protein kinase C activity, the direct involve-
ment of this kinase in the apoptosis-enhancing e¡ect
of the Uor is unlikely. On the other hand, calcium ion
is implicated as a mediator of apoptosis due to its
ability to perturb mitochondrial functions, notably
the activity of the permeability transition pore
[42,43]. Apart from calcium ion, the inositol phos-
phates also needed to be considered since several of
them are known to possess second messenger func-
tions. Obviously, further experiments are necessary
to investigate the role of phospholipase C derived
signals in the modulation of apoptosis.
In summary, we have studied the functional prop-
erties of type 1 Uor expressed in cultured human ep-
ithelial tumor cells. Evidence is provided that this
epithelial Uor possesses a pro-apoptotic function
that is mediated by phospholipase C rather than
through the reduction of cAMP. The present study,
together with previous reports on the role of opioid
receptors in apoptosis, suggest that this family of G-
protein-coupled receptors may play an essential role
in cellular stress response, in addition to the well
known role in nociception and other neurological
activities.
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